Active Filter(s):
Details:
Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist. Ifetroban exhibits high affinity for TPr on many cell types including platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity.
Lead Product(s): Ifetroban Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Caldolor (ibuprofen) is an USFDA approved NSAID, functions by the inhibiting of cyclooxygenase (COX-1 and COX-2), for the treatment of fever & pain in infants.
Lead Product(s): Ibuprofen
Therapeutic Area: Neurology Product Name: Caldolor
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.
Lead Product(s): Granisetron
Therapeutic Area: Gastroenterology Product Name: Sancuso
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Verity Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 09, 2022
Details:
Vibativ® (telavancin) Injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA.
Lead Product(s): Telavancin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Vibativ
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Tabuk Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Details:
Under the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO (Granisetron) and will assume full commercial responsibility for the product - including its marketing, promotion, distribution, manufacturing and medical support activities.
Lead Product(s): Granisetron
Therapeutic Area: Gastroenterology Product Name: Sancuso
Highest Development Status: Approved Product Type: Small molecule
Recipient: Kyowa Kirin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 04, 2022
Details:
Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as for the reduction of fever.
Lead Product(s): Ibuprofen
Therapeutic Area: Neurology Product Name: Caldolor
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
RediTrex (methotrexate) is a folate analog metabolic inhibitor is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.
Lead Product(s): Methotrexate
Therapeutic Area: Immunology Product Name: RediTrex
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including HABP and VABP that can result from COVID-19, flu and other infections.
Lead Product(s): Telavancin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Vibativ
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2021
Details:
The collaboration aims at providing hospitals and clinics that use Caldolor® injection for the treatment of COVID-19 patients easy access financial arrangements to combat medical requirements.
Lead Product(s): Ibuprofen
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 31, 2020